To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Conditions
- Type 2 Diabetes
- Dyslipidemias
Interventions
- DRUG: Empagliflozin 25 MG
- DRUG: Ezetimibe/Rosuvastatin 10/10mg
- DRUG: Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
Sponsor
Hyundai Pharm
Collaborators